文献速递消化系统肿瘤

糖尿病及二甲双胍使用对II-III期结肠癌患者复发和结局的影响——三项辅助治疗试验的汇总分析

Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.
PubMed 文献 · Eur J Cancer · 2022-03-11

该研究对三项随机辅助治疗试验中5922例II-III期结肠癌患者进行患者水平汇总分析,中位随访6.8年。结果显示,合并糖尿病的结肠癌患者无复发生存时间(TTR)和总生存期(OS)显著缩短;未使用二甲双胍的糖尿病患者TTR和OS显著更差,而使用二甲双胍者这些不良结局未达统计学显著。数据提示二甲双胍可能减轻糖尿病对结肠癌患者结局的不利影响。

要点

  • 合并糖尿病的II-III期结肠癌患者TTR(adjHR 1.21)和OS(adjHR 1.29)显著缩短。
  • 未使用二甲双胍的糖尿病患者TTR(adjHR 1.28)和OS(adjHR 1.41)显著更差。
  • 使用二甲双胍者TTR(adjHR 1.16)和OS(adjHR 1.19)未达统计学显著。

核心结论

  • 合并糖尿病的结肠癌患者不仅总生存期显著更差,无复发生存时间也显著缩短。
  • 数据提示二甲双胍可能减轻糖尿病对结肠癌患者结局的不利影响。

研究设计与样本

  • 患者水平汇总分析,纳入三项随机辅助治疗试验。
  • 所有患者均接受II期或III期结肠癌根治性切除术,并接受标准辅助氟嘧啶和奥沙利铂(±西妥昔单抗)治疗。
  • 共纳入5922例结肠癌患者,中位随访6.8年;621例(10.5%)在结肠癌诊断时合并糖尿病。
  • 合并糖尿病患者中,327例(52.7%)为二甲双胍使用者,294例(47.3%)为非二甲双胍使用者。

主要发现

  • 合并糖尿病的结肠癌患者与无糖尿病患者相比,TTR显著更短(adjHR 1.21;95%CI 1.03-1.42;p=0.017),OS显著更差(adjHR 1.29;95%CI 1.09-1.52;p=0.003)。
  • 未使用二甲双胍的糖尿病患者与无糖尿病患者相比,TTR显著更差(adjHR 1.28;95%CI 1.02-1.60;p=0.032),OS显著更差(adjHR 1.41;95%CI 1.13-1.77;p=0.003)。
  • 使用二甲双胍的糖尿病患者与无糖尿病患者相比,TTR(adjHR 1.16;95%CI 0.94-1.43;p=0.168)和OS(adjHR 1.19;95%CI 0.95-1.48;p=0.127)的差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes mellitus (DM) has been associated with increased colorectal cancer (CRC) risk and worse prognosis in metastatic CRC patients. In this large, pooled analysis of non-metastatic colon cancer (CC) patients, we investigated the impact of DM and metformin treatment on recurrence and survival. PATIENTS AND METHODS: A patient-level pooled analysis from three randomised adjuvant trials was performed. All patients had resection with curative intent of stage II or III CC and were treated with standard adjuvant fluoropyrimidine and oxaliplatin (±cetuximab). We investigated the impact of DM and metformin treatment on time to recurrence (TTR) and overall survival (OS). RESULTS: Of 5922 CC patients who had a median follow-up of 6.8 years, 621 patients (10.5%) had DM at CC diagnosis. Of those with DM, 327 patients (52.7%) were defined as metformin users and 294 patients (47.3%) as non-metformin users. CC patients with DM had a significantly shorter TTR (adjHR: 1.21; 95% CI, 1.03-1.42; p = 0.017) and OS (adjHR: 1.29; 95% CI, 1.09-1.52; p = 0.003) compared to non-diabetic CC patients. Diabetic CC patients not receiving metformin had a significantly worse TTR (adjHR: 1.28; 95% CI, 1.02-1.60; p = 0.032) and OS (adjHR: 1.41; 95% CI, 1.13-1.77; p = 0.003) as compared to non-diabetic patients. These worse outcomes were not significant in metformin users (TTR: adjHR: 1.16; 95% CI, 0.94-1.43; p = 0.168; OS: adjHR: 1.19; 95% CI, 0.95-1.48, p = 0.127). CONCLUSIONS: CC patients with DM had not only a significantly worse survival but also TTR. Furthermore, our data suggest that metformin may attenuate the detrimental effect of DM on CC patient outcomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Christou N, Bergen ES, Canton C, et al. Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. Eur J Cancer. 2022. PMID: 35279470. doi:10.1016/j.ejca.2022.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。